Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00645749 · ClinicalTrials.gov registry record · Phase 1
Helminth-induced Immunomodulation Therapy (HINT) in Relapsing-remitting Multiple Sclerosis
A Phase 1 study, sponsored by University of Wisconsin, Madison.
- Completed
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
NCT00645749 is a Phase 1 study that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 17 participants.
The verdict
NCT00645749, a Phase 1 study, has completed, sponsored by University of Wisconsin, Madison.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
The hypothesis of this study is that helminth-induced immunomodulation therapy (HINT) will be safe and effective when administered orally in patients with relapsing-remitting multiple sclerosis (RRMS).
Interventions
- BIOLOGICAL Helminth ova
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2008-07 |
| Est. Completion | 2015-08-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00645749
The ClinicalTrials.gov registry entry for NCT00645749 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Helminth ova is the first listed.
NCT00645749 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00645749 about?
NCT00645749 is a clinical study titled "Helminth-induced Immunomodulation Therapy (HINT) in Relapsing-remitting Multiple Sclerosis". The hypothesis of this study is that helminth-induced immunomodulation therapy (HINT) will be safe and effective when administered orally in patients with relapsing-remitting multiple sclerosis (RRMS).
What is the current status of trial NCT00645749?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2008-07. Estimated completion is 2015-08-13.
What interventions are being tested in trial NCT00645749?
The interventions under investigation include: Helminth ova (BIOLOGICAL).
Who is sponsoring clinical trial NCT00645749?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.